Johnson & Johnson announced FDA approval of a supplemental new drug application for Caplyta (lumateperone) for the prevention of relapse in schizophrenia, based on compelling long-term clinical data and reported…
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to IMAAVY® (nipocalimab-aahu), marking a significant milestone as the first therapy to receive this…
Johnson & Johnson announced promising long-term efficacy and safety data for Icotyde (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23 receptor for plaque psoriasis treatment.…
When standard depression medications fail, patients face a devastating reality. Approximately one-third of people with major depressive disorder do not adequately respond to conventional antidepressants, leaving them trapped in a…
According to MedPage Today, the FDA sent a letter to the manufacturer of the Johnson & Johnson COVID-19 vaccine on Monday containing a warning about its link to Guillain-Barre syndrome…
The Johnson & Johnson (J&J) vaccine was welcomed as the third alternative to Moderna and Pfizer vaccines but with even more perks. It was a one-time shot that used “viral…
Over one year ago, the news became saturated with information on COVID-19, a novel coronavirus pandemic that has since swept the globe. At the time of this article, there are…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
